‹ ›
MYP_138361
← PREVIOUS NEXT → BACK
Basic Information
T-20S138Y
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
36 amino acids
C208H302N50O64
Standard
Sequence
YTSLIHSLIEEYQNQQEKNEQELLELDKWASLWNWF
Physicochemical Analysis
4526.92 Da
4.30
-5.14
-5.41
-0.1427
-0.89
0.48
-0.03
51.95
89.44
0.1667
19480.00
19480.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1894.02
-13.00
63.0
60.0
151.0
322.0
10.0
42.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0071442 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
11676
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor
HIV-1 NL4-3 WT; HeLa-derived MAGI cells
0.025±0.009 μM
EC50 (MAGI assay)
PaperDesign of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. PMID19073606 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19073606/
RECORD: Rec_0088024 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 NL4-3 N43D; HeLa-derived MAGI cells
>1 μM
EC50 (MAGI assay)
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperDesign of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. | Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M. | J Biol Chem. 2009 Feb 20;284(8):4914-20. | DOI:10.1074/jbc.M807169200 | PMID:19073606 PMID19073606 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19073606/
RECORD: Rec_0105831 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1 NL4-3 WT and resistant V38A/N43D/N43D-S138A variants; HeLa-derived MAGI cells
EC50 panel (MAGI assay)
PaperDesign of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20 PMID19073606 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19073606/
RECORD: Rec_0117349 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 NL4-3 V38A; HeLa-derived MAGI cells
0.516±0.223 μM
EC50 (MAGI assay)
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperDesign of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. | Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M. | J Biol Chem. 2009 Feb 20;284(8):4914-20. | DOI:10.1074/jbc.M807169200 | PMID:19073606 PMID19073606 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19073606/
RECORD: Rec_0120932 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1 NL4-3 N43D/S138A; HeLa-derived MAGI cells
>1 μM
EC50 (MAGI assay)
PMID19073606 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19073606/
1 2 3 NEXT LAST
Showing 5 records · Page 1 of 3